| Triple-drug therapy with bevacizumab, irinotecan, and temozolomide plus tumor treating fields for recurrent glioblastoma: a retrospective study G Lu, M Rao, P Zhu, B Liang, RT El-Nazer, E Fonkem, MB Bhattacharjee, ... Frontiers in neurology 10, 42, 2019 | 55 | 2019 |
| Gamma knife stereotactic radiosurgery in combination with bevacizumab for recurrent glioblastoma SAL Morris, P Zhu, M Rao, M Martir, JJ Zhu, S Hsu, LY Ballester, AL Day, ... World neurosurgery 127, e523-e533, 2019 | 41 | 2019 |
| Circulating tumour DNA, microRNA and metabolites in cerebrospinal fluid as biomarkers for central nervous system malignancies S Zorofchian, F Iqbal, M Rao, PP Aung, Y Esquenazi, LY Ballester Journal of Clinical Pathology 72 (4), 271-280, 2019 | 35 | 2019 |
| Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report M Rao, M Bhattacharjee, S Shepard, S Hsu Oncotarget 10 (57), 6038, 2019 | 27 | 2019 |
| Quantitative assessment of in vivo human anterior cruciate ligament autograft remodeling: a 3-dimensional UTE-T2* imaging study RJ Warth, P Zandiyeh, M Rao, RE Gabr, S Tashman, M Kumaravel, ... The American Journal of Sports Medicine 48 (12), 2939-2947, 2020 | 17 | 2020 |
| The 2016 world health organization classification of tumors of the central nervous system: A practical approach for gliomas, part 1. basic tumor genetics OJ Arevalo, R Valenzuela, Y Esquenazi, M Rao, B Tran, J Zhu, ... Neurographics 7 (5), 334-343, 2017 | 12 | 2017 |
| The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a practical approach for gliomas, part 2. Isocitrate dehydrogenase status—imaging … OJ Arevalo, R Valenzuela, Y Esquenazi, M Rao, B Tran, J Zhu, ... Neurographics 7 (5), 344-349, 2017 | 9 | 2017 |
| Funding sources are under-reported in randomised clinical trials of biological treatments in sports medicine: a systematic review HA Anz, HA Ahmad, AM Kozemchak, M Rao, RJ Warth, CD Harner Journal of ISAKOS 5 (6), 371-377, 2020 | 5 | 2020 |
| Gamma knife stereotactic radiosurgery in combination with bevacizumab for recurrent glioblastoma. World Neurosurg 127: e523–e533 SL Morris, P Zhu, M Rao, M Martir, JJ Zhu, S Hsu, LY Ballester, AL Day, ... | 5 | 2019 |
| Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab G Lu, P Zhu, M Rao, N Linendoll, LM Buja, MB Bhattacharjee, RE Brown, ... Journal of neuro-oncology 160 (1), 221-231, 2022 | 3 | 2022 |
| Neuroprotective Efficacy of Clitoria Ternacea Root Extract on Hippocampal CA3 Neurons–A Quantitative Study in Mice S Hemamalini, MS Rao Journal of Morphological Sciences 35 (02), 090-095, 2018 | 2 | 2018 |
| P09. 63 Postmortem evaluation of end-organ toxicity in patients with glioblastoma treated with temozolomide, bevacizumab and irinotecan G Lu, M Rao, P Zhu, X Tian, N Linendoll, M Pilichowska, WF Glass, ... Neuro-oncology, iii84, 2017 | 2 | 2017 |
| Survival benefit with triple chemotherapy and TTFields for glioblastoma G Lu, M Rao, LC Delumpa, Z Liu, S Hsu, JJ Zhu NEURO-ONCOLOGY 18, 149-149, 2016 | 2 | 2016 |
| NIMG-24. Pathology confirmed radiographic diagnosis of true progression and pseudo-progression made by advanced brain tumor imaging RF Valenzuela, L Ocasio, MB Bhattacharjee, G Lu, M Rao, N Tandon, ... Neuro-Oncology 19 (suppl_6), vi147-vi147, 2017 | 1 | 2017 |
| Final results from the dose-escalation stage of a phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma. SA Goldlust, LB Nabors, N Mohile, TL Benkers, SH Hsu, S Silberman, ... Journal of Clinical Oncology 35 (15_suppl), 2021-2021, 2017 | 1 | 2017 |
| Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma SA Goldlust, LB Nabors, S Hsu, N Mohile, PJ Duic, T Benkers, S Singer, ... Neuro-Oncology Advances 6 (1), vdae009, 2024 | | 2024 |
| Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report M Rao, M Bhattacharjee, S Shepard, S Hsu Oncotarget 14, 438, 2023 | | 2023 |
| Cerebrospinal fluid analysis (vol 1, pg 422, 2021) S Zorofchian, F Iqbal, M Rao AMERICAN FAMILY PHYSICIAN 103 (12), 713-713, 2021 | | 2021 |
| NCMP-09. POSTMORTEM STUDY OF ORGAN SPECIFIC TOXICITY IN GLIOBLASTOMA PATIENTS TREATED WITH A COMBINATION OF TEMOZOLOMIDE, BEVACIZUMAB AND IRINOTECAN JJ Zhu, G Lu, M Rao, P Zhu, N Linendoll, X Tian, M Pilichowska, J Wu, ... Neuro-Oncology 22 (Supplement_2), ii124-ii125, 2020 | | 2020 |
| Objective assessment of ACL graft status after ACL reconstruction using T2* MRI RJ Warth, P Zandiyeh, M Rao, R Gabr, S Tashman, M Kumaravel, ... | | 2020 |
